Henri joined Royalty Pharma in 2021. Previously, he was a Senior Analyst at Pharmakon Advisors, an affiliate of Royalty Pharma, and the leading investor in Life Sciences debt. Henri began his career in the healthcare investment banking coverage group at Credit Suisse. Henri has a B.A. in Public Policy from Stanford University.